CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) is a healthcare company (biotechnology) based in Switzerland. The share price is $40.42, up 0.11% on the day, which values the company at $3.92B. Price as of 17 Nov 2026, 17:36 UTC, from Yahoo Finance.
Key facts
- Share price
- $40.42+0.11% today
- Market value
- $3.92B
- 200-week average
- $52.9324% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
CRISPR Therapeutics AG in more detail
CRSP trades at -11.0× next year's expected earnings, 155.7× sales. It sits 24% below its 200-week average of $52.93.
In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.
1 of the superinvestors tracked here hold CRSP, including Cathie Wood (3.2% of the portfolio).
Superinvestors holding CRSP
1 of the investors tracked here report a position in their latest 13F filing.
- Cathie Wood ARK Invest3.20% of portfolio · $556.3M · added · Q3 2026
Health Care companies of similar size
- Merit Medical SystemsMMSI
- Edgewise TherapeuticsEWTX
- LivaNovaLIVN
- Ionis PharmaceuticalsIONS
- Dianthus TherapeuticsDNTH
- MiniMed GroupMMED
- Adaptive BiotechnologiesADPT
- HeartflowHTFL
- Travere TherapeuticsTVTX
- Option Care HealthOPCH
- Legend BiotechLEGN
- Definium TherapeuticsDFTX
Side by side:CRSP vs HTFL (CRISPR Therapeutics AG vs Heartflow)CRSP vs TVTX (CRISPR Therapeutics AG vs Travere Therapeutics)CRSP vs ADPT (CRISPR Therapeutics AG vs Adaptive Biotechnologies)CRSP vs MMED (CRISPR Therapeutics AG vs MiniMed Group)CRSP vs OPCH (CRISPR Therapeutics AG vs Option Care Health)
All health care companies by market valueLargest companies in SwitzerlandAll stocks A–Z
CRISPR Therapeutics AG (CRSP): questions and answers
What is CRISPR Therapeutics AG's market cap?
CRISPR Therapeutics AG is valued at $3.92B at a share price of $40.42.
Is CRSP above its 200-week moving average?
No. CRSP is 23.7% below its 200-week average of $52.93. Long-term investors watch that line because strong companies rarely trade below it for long.
Does CRSP pay a dividend?
CRISPR Therapeutics AG does not currently pay a regular dividend.
Which famous investors own CRSP?
In their latest quarterly filings, Cathie Wood (3.2% of the portfolio) hold CRSP. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “CRISPR Therapeutics AG (CRSP) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CRSP
Underlying data: Yahoo Finance; company filings with the SEC.